Nanovibronix (NASDAQ:NAOV) (NASDAQ: NAOV) is a medical technology company specializing in noninvasive therapeutic and surgical solutions powered by acoustic resonance. The company develops, manufactures and markets a range of ultrasound-based devices designed to address pain management, wound healing, urinary catheter-related infections and respiratory complications. By harnessing low-frequency ultrasound energy, Nanovibronix products aim to deliver targeted tissue stimulation that can accelerate healing processes and improve patient outcomes without the need for pharmaceuticals or invasive procedures.
The company’s flagship offerings include the Pain Relief System, which utilizes extracorporeal acoustic resonance to reduce inflammation and alleviate chronic and acute musculoskeletal discomfort. In its urology division, Nanovibronix markets the UroShield™ catheter, an embedded ultrasound-enabled indwelling catheter designed to inhibit biofilm formation and reduce the incidence of catheter-associated urinary tract infections. In respiratory care, the TrueWave™ therapy system provides airway clearance by transmitting vibration through endotracheal and tracheostomy tubes, helping to prevent ventilator-associated complications.
Founded in Israel, Nanovibronix has expanded its global footprint with operations and distribution channels across North America, Europe and parts of Asia. The company’s research and development activities are supported by a combination of internal laboratories and partnerships with academic institutions and clinical centers. Over the years, Nanovibronix has obtained regulatory approvals in key markets, including FDA clearance for multiple product lines and CE marking for distribution throughout the European Union.
Nanovibronix is led by a management team with extensive experience in medical device development, clinical research and regulatory affairs. The company’s board of directors includes seasoned executives from the healthcare and life sciences sectors. Looking ahead, Nanovibronix continues to pursue new therapeutic indications and strategic collaborations aimed at expanding its product portfolio and driving adoption of acoustic resonance technologies in mainstream medical practice.
